Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Factors for a broad technology assessment of comprehensive genomic profiling in advanced cancer, a systematic review
LF van Schaik, EG Engelhardt, EA Wilthagen… - Critical reviews in …, 2024 - Elsevier
Abstract Comprehensive Genomic Profiling (CGP) allows for the identification of many
targets. Reimbursement decision-making is, however, challenging because besides the …
targets. Reimbursement decision-making is, however, challenging because besides the …
First-line genomic profiling in previously untreated advanced solid tumors for identification of targeted therapy opportunities
J Matsubara, K Mukai, T Kondo, M Yoshioka… - JAMA Network …, 2023 - jamanetwork.com
IMPORTANCE Precision oncology using comprehensive genomic profiling (CGP) by next-
generation sequencing is aimed at companion diagnosis and genomic profiling. The clinical …
generation sequencing is aimed at companion diagnosis and genomic profiling. The clinical …
Administrative aspects of molecular diagnostics—Oversight, regulatory approval process, clinical and operational workflows, and payment models
L Wilfong, L Baggett, P Reena, R Murphy… - JCO Oncology …, 2024 - ascopubs.org
This paper discusses the administrative aspects of molecular diagnostics in oncology,
including US Food and Drug Administration (FDA) oversight, the regulatory approval …
including US Food and Drug Administration (FDA) oversight, the regulatory approval …
Clinical impact of comprehensive molecular profiling in adolescents and young adults with sarcoma
Sarcomas are a heterogenous group of tumours that commonly carry poor prognosis with
limited therapeutic options. Adolescents and young adults (AYAs) with sarcoma are a …
limited therapeutic options. Adolescents and young adults (AYAs) with sarcoma are a …
Real-World Impact of Comprehensive Genomic Profiling on Biomarker Detection, Receipt of Therapy, and Clinical Outcomes in Advanced Non–Small Cell Lung …
J Wallenta Law, B Bapat, C Sweetnam… - JCO Precision …, 2024 - ascopubs.org
PURPOSE Therapeutic decision making for patients with advanced non–small cell lung
cancer (aNSCLC) includes a growing number of options for genomic, biomarker-guided …
cancer (aNSCLC) includes a growing number of options for genomic, biomarker-guided …
Examining external control arms in oncology: A sco** review of applications to date
Abstract Objectives Randomized controlled trials (RCTs) are the gold standard for
evaluating the comparative efficacy and safety of new cancer therapies. However, enrolling …
evaluating the comparative efficacy and safety of new cancer therapies. However, enrolling …
[HTML][HTML] Longer survival with precision medicine in late-stage cancer patients
CK Mapendano, AK Nøhr, M Sønderkær, A Pagh… - ESMO open, 2025 - Elsevier
Background In a per-protocol analysis of molecularly profiled patients with treatment-
refractory, end-stage cancer discussed at the National Molecular Tumor Board (NMTB), we …
refractory, end-stage cancer discussed at the National Molecular Tumor Board (NMTB), we …
Comprehensive genomic profiling of Taiwanese triple negative breast cancers with medium-and large-sized sequencing panels: a comparative study of actionable …
CC Huang, YC Yeh, YF Tsai, YS Lin, TC Chao, CY Liu… - 2024 - researchsquare.com
Methods Triple negative breast cancer (TNBC) patients from the VGH-TAYLOR study were
initially assayed by a medium-sized CGP panel (Oncomine Comprehensive Panel, OCP …
initially assayed by a medium-sized CGP panel (Oncomine Comprehensive Panel, OCP …